Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line

Clinical evidence regarding eribulin treatment for patients with soft tissue sarcoma (STS) is limited to those with L-sarcoma (leiomyosarcoma and liposarcoma) who have completed at least two chemotherapies. Whether histological subtypes and treatment lines affect the efficacy and safety of eribulin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Clin Oncol
Autores principales: Nakano, Kenji, Hayakawa, Keiko, Funauchi, Yuki, Tanizawa, Taisuke, Ae, Keisuke, Matsumoto, Seiichi, Tomomatsu, Junichi, Ono, Makiko, Taira, Shinichiro, Nishizawa, Masatoshi, Wang, Xiaofei, Ohmoto, Akihiro, Sato, Yasuyoshi, Fukuda, Naoki, Urasaki, Tetsuya, Takahashi, Shunji
Formato: Artigo
Lenguaje:Inglês
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709564/
https://ncbi.nlm.nih.gov/pubmed/33282288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2175
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares